• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor.

作者信息

Wright H T, Qian H X, Huber R

机构信息

Department of Biochemistry and Molecular Biophysics, Virginia Commonwealth University, Richmond 23298.

出版信息

J Mol Biol. 1990 Jun 5;213(3):513-28. doi: 10.1016/s0022-2836(05)80212-8.

DOI:10.1016/s0022-2836(05)80212-8
PMID:2352279
Abstract

The crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin, has been determined to a resolution of 2.8 A by the isomorphous replacement method and preliminary refinement. The structure closely resembles that of the cleaved form of alpha-1-proteinase inhibitor, with some important exceptions. The disposition of the new carboxyl chain terminus liberated by proteolysis is different with respect to the central beta-sheet A in the structures of these two molecules. In alpha-1-proteinase inhibitor, the new chain terminus inserts in beta-sheet A to add a middle strand to the sheet. In plakalbumin, this strand remains free near the site at which the cleavage occurs. A structural basis for this difference in behavior is proposed from the structures and sequences of these two molecules and other members of the serpin family. The structures and positions of the putative signal peptide of ovalbumin, the several post-translational modifications, and the relationship of the intron-exon patterns of plakalbumin and alpha-1-proteinase inhibitor to their protein structures are also described.

摘要

相似文献

1
Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor.
J Mol Biol. 1990 Jun 5;213(3):513-28. doi: 10.1016/s0022-2836(05)80212-8.
2
Crystal structure of uncleaved ovalbumin at 1.95 A resolution.分辨率为1.95埃的未切割卵清蛋白晶体结构。
J Mol Biol. 1991 Oct 5;221(3):941-59. doi: 10.1016/0022-2836(91)80185-w.
3
Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function.人α1-蛋白酶抑制剂。两种晶体变体的晶体结构分析、分子模型及功能影响的初步分析。
J Mol Biol. 1984 Aug 15;177(3):531-57.
4
Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins.
J Mol Biol. 1991 Apr 5;218(3):595-606. doi: 10.1016/0022-2836(91)90704-a.
5
Modeling the intact form of the alpha 1-proteinase inhibitor.模拟α1-蛋白酶抑制剂的完整形式。
Protein Eng. 1990 May;3(6):469-77. doi: 10.1093/protein/3.6.469.
6
Secondary structure changes stabilize the reactive-centre cleaved form of SERPINs. A study by 1H nuclear magnetic resonance and Fourier transform infrared spectroscopy.二级结构变化稳定了丝氨酸蛋白酶抑制剂(SERPINs)的反应中心裂解形式。一项通过氢-1核磁共振和傅里叶变换红外光谱进行的研究。
J Mol Biol. 1992 Dec 20;228(4):1235-54. doi: 10.1016/0022-2836(92)90329-i.
7
Crystal structure of ovalbumin as a model for the reactive centre of serpins.作为丝氨酸蛋白酶抑制剂反应中心模型的卵清蛋白晶体结构。
Nature. 1990 Sep 6;347(6288):99-102. doi: 10.1038/347099a0.
8
A 1H NMR probe for mobility in the reactive center loops of serpins: spin-echo studies of native and modified forms of ovalbumin and alpha 1-proteinase inhibitor.
Biochemistry. 1991 Sep 17;30(37):9054-60. doi: 10.1021/bi00101a021.
9
Structural basis of latency in plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1中潜伏状态的结构基础。
Nature. 1992 Jan 16;355(6357):270-3. doi: 10.1038/355270a0.
10
Preliminary x-ray analysis of single crystals of ovalbumin and plakalbumin.卵清蛋白和扁白蛋白单晶的初步X射线分析。
J Biol Chem. 1983 May 10;258(9):5864-6.

引用本文的文献

1
Unravelling the fibrillation mechanism of ovalbumin in the presence of mercury at its isoelectric pH.揭示卵清蛋白在等电pH值下与汞共存时的纤维化机制。
RSC Adv. 2020 Apr 24;10(28):16415-16421. doi: 10.1039/c9ra10655c. eCollection 2020 Apr 23.
2
Comparative Study of the Interactions between Ovalbumin and five Antioxidants by Spectroscopic Methods.比较研究卵清蛋白与五种抗氧化剂的相互作用的光谱方法。
J Fluoresc. 2017 Jan;27(1):213-225. doi: 10.1007/s10895-016-1948-3. Epub 2016 Oct 8.
3
Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.
抑制性丝氨酸蛋白酶抑制剂。对其折叠、聚合、调节和清除的新见解。
Biochem J. 2016 Aug 1;473(15):2273-93. doi: 10.1042/BCJ20160014.
4
Comparative study of the interactions between ovalbumin and three alkaloids by spectrofluorimetry.应用荧光光谱法比较研究卵清蛋白与三种生物碱的相互作用。
Mol Biol Rep. 2013 Apr;40(4):3409-18. doi: 10.1007/s11033-012-2418-x. Epub 2012 Dec 25.
5
The behavior of R-ovalbumin and its individual components A1, A2, and A3 in urea solution: kinetics and equilibria.R-卵清蛋白及其单个组分A1、A2和A3在尿素溶液中的行为:动力学与平衡
J Protein Chem. 2003 Apr;22(3):207-14. doi: 10.1023/a:1025076621515.
6
Probing the serpin structural-transition mechanism in ovalbumin mutant R339T by proteolytic-cleavage kinetics of the reactive-centre loop.通过反应中心环的蛋白水解切割动力学探究卵清蛋白突变体R339T中的丝氨酸蛋白酶抑制剂结构转变机制。
Biochem J. 2002 Apr 15;363(Pt 2):403-9. doi: 10.1042/0264-6021:3630403.
7
Recombinant human pigment epithelium-derived factor (PEDF): characterization of PEDF overexpressed and secreted by eukaryotic cells.重组人色素上皮衍生因子(PEDF):真核细胞过表达并分泌的PEDF的特性
Protein Sci. 1996 Dec;5(12):2575-82. doi: 10.1002/pro.5560051220.
8
Serpin alpha 1proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy.通过内源色氨酸荧光光谱法探测丝氨酸蛋白酶抑制剂α1抗胰蛋白酶。
Protein Sci. 1996 Nov;5(11):2226-35. doi: 10.1002/pro.5560051109.
9
Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.通过比较模型构建对α-1-抗糜蛋白酶:前列腺特异性抗原复合物进行结构研究。
Protein Sci. 1996 May;5(5):836-51. doi: 10.1002/pro.5560050505.
10
Neuroserpin, an axonally secreted serine protease inhibitor.神经丝氨酸蛋白酶抑制剂,一种轴突分泌的丝氨酸蛋白酶抑制剂。
EMBO J. 1996 Jun 17;15(12):2944-53.